NZ585977A - Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis - Google Patents

Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis

Info

Publication number
NZ585977A
NZ585977A NZ585977A NZ58597708A NZ585977A NZ 585977 A NZ585977 A NZ 585977A NZ 585977 A NZ585977 A NZ 585977A NZ 58597708 A NZ58597708 A NZ 58597708A NZ 585977 A NZ585977 A NZ 585977A
Authority
NZ
New Zealand
Prior art keywords
ala
ala ester
ester
product
cancer
Prior art date
Application number
NZ585977A
Other languages
English (en)
Inventor
Jo Klaveness
Gry Stensrud
Aslak Godal
Jon Erik Braenden
Bjorn Klem
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Priority to NZ600028A priority Critical patent/NZ600028A/xx
Publication of NZ585977A publication Critical patent/NZ585977A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ585977A 2007-12-12 2008-12-12 Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis NZ585977A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ600028A NZ600028A (en) 2007-12-12 2008-12-12 Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0724279.5A GB0724279D0 (en) 2007-12-12 2007-12-12 Use
PCT/GB2008/004113 WO2009074811A2 (en) 2007-12-12 2008-12-12 Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis

Publications (1)

Publication Number Publication Date
NZ585977A true NZ585977A (en) 2012-06-29

Family

ID=39016493

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ585977A NZ585977A (en) 2007-12-12 2008-12-12 Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis
NZ600028A NZ600028A (en) 2007-12-12 2008-12-12 Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ600028A NZ600028A (en) 2007-12-12 2008-12-12 Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis

Country Status (12)

Country Link
US (2) US20110020441A1 (enExample)
EP (2) EP2684573A3 (enExample)
JP (2) JP5686603B2 (enExample)
KR (1) KR20100095443A (enExample)
CN (2) CN104306968A (enExample)
AU (1) AU2008334426B2 (enExample)
BR (1) BRPI0821668A2 (enExample)
CA (1) CA2708137C (enExample)
GB (1) GB0724279D0 (enExample)
NZ (2) NZ585977A (enExample)
RU (2) RU2521228C2 (enExample)
WO (1) WO2009074811A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0724279D0 (en) * 2007-12-12 2008-01-23 Photocure Asa Use
GB0823472D0 (en) 2008-12-23 2009-01-28 Photocure Asa Product
US20120136055A1 (en) 2009-06-11 2012-05-31 Photocure Asa Semi-solid compositions and pharmaceutical products
CN102802612A (zh) * 2009-06-11 2012-11-28 光治疗Asa公司 含有5-氨基酮戊酸的固态组合物
EP2283830A1 (en) * 2009-07-23 2011-02-16 Actogenix N.V. Aqueous enteric capsule coating
DE102009028076A1 (de) * 2009-07-29 2011-02-03 Evonik Röhm Gmbh Beschichtungsmittel zum Tauchbeschichten von Kapselhälften
US9107451B2 (en) 2009-07-29 2015-08-18 Evonik Röhm Gmbh Coating composition for the dip coating of capsule halves
WO2011107478A1 (en) 2010-03-01 2011-09-09 Photocure Asa Cosmetic compositions
WO2011161220A1 (en) 2010-06-23 2011-12-29 Photocure Asa Hyperosmotic preparations comprising 5 -amino levulinic acid or derivative as photosensitizing agent
ES2620780T3 (es) * 2010-07-09 2017-06-29 Photocure Asa Dispositivos que contienen composiciones secas para su uso en terapia fotodinámica
KR101254758B1 (ko) * 2011-02-28 2013-04-15 부산대학교병원 광역동치료의 광증감제로 사용하기 위한 이디티에이를 이용한 아미노레불리닉산 테트라머
RU2454255C1 (ru) * 2011-05-30 2012-06-27 Виктор Александрович Борисов Способ фотодинамической терапии злокачественных новообразований
US9492682B2 (en) * 2011-09-14 2016-11-15 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
AU2013298525B2 (en) * 2012-08-03 2017-12-14 Photocure Asa Compounds
US20140067024A1 (en) 2012-08-30 2014-03-06 Photocure Asa Dual panel photodynamic therapy lamp
GB201221123D0 (en) 2012-11-23 2013-01-09 Photocure As Device for photodynamic treatment
EP2968128A4 (en) * 2013-03-12 2016-11-16 Applied Biores Inc CHELATING COFFEE FOR IMPROVED DRUG DISPERSION
JP6352912B2 (ja) * 2013-06-21 2018-07-04 国立大学法人 岡山大学 異常活性化細胞検出による悪性腫瘍の検査方法および異常活性化細胞除去環流返血治療装置
US20150364550A1 (en) * 2014-06-16 2015-12-17 Infineon Technologies Ag Optimized layer for semiconductor
CN104306971B (zh) * 2014-10-29 2017-02-15 青岛大学附属医院 一种配合光动力疗法抗宫颈癌的药物组合物
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
PL3362145T3 (pl) 2015-10-15 2021-07-19 Dusa Pharmaceuticals, Inc. Regulowany oświetlacz do terapii fotodynamicznej i diagnostyki
DK3389716T3 (da) 2015-12-17 2022-04-11 Photocure Asa Fremgangsmåde til fotodynamisk terapi (pdt) for blærekræft
GB201522398D0 (en) 2015-12-18 2016-02-03 Photocure As Device for photodynamic therapy
GB2546128A (en) * 2016-09-28 2017-07-12 Photocure Asa Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
CN107434753A (zh) * 2017-07-26 2017-12-05 南京大学 5‑氨基乙酰丙酸及其衍生物的泡腾片及其制备方法
CN107854471A (zh) * 2017-10-26 2018-03-30 郭裴哲 一种治疗宫颈糜烂的药物制剂及用途
CN107812190A (zh) * 2017-11-10 2018-03-20 中国医学科学院生物医学工程研究所 一种用于直肠肿瘤治疗的光动力试剂盒及制备方法
US10357567B1 (en) * 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy
CN108079298B (zh) * 2018-01-26 2021-05-25 南方医科大学南方医院 一种经皮光动力药物5-氨基酮戊酸己酯盐酸盐醇质体及其制备方法和应用
GB201905940D0 (en) * 2019-04-29 2019-06-12 Intract Pharma Ltd 5-aminolevulinic acid for the local treatment of inflammatory bowel disease
KR102265592B1 (ko) * 2020-10-29 2021-06-17 김진왕 5-아미노레불린산 수화염화물을 포함하는 조성물
WO2023079513A1 (en) * 2021-11-05 2023-05-11 Dusa Pharmaceuticals, Inc. Photodynamic therapy illuminator devices and methods
AU2023374228A1 (en) * 2022-11-04 2025-05-15 Sun Pharmaceutical Industries, Inc. Photodynamic therapy methods
CN115671059B (zh) * 2022-11-17 2024-06-11 兆科药业（合肥）有限公司 一种盐酸氨酮戊酸冻干制剂及制备方法
CN115998904A (zh) * 2023-01-17 2023-04-25 武汉理工大学 一种光敏剂联合抗生素智能抗菌水凝胶及其制备方法和应用
CN116271547A (zh) * 2023-03-17 2023-06-23 丹东英发科技开发有限公司 高导光性能之医用导光凝胶和其制备方法
CN119264000B (zh) * 2024-09-30 2025-10-14 广东溢多利生物科技股份有限公司 一种5-ala液体的稳定剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6133111A (ja) * 1984-06-18 1986-02-17 Hisamitsu Pharmaceut Co Inc 直腸投与製剤
US4765978A (en) * 1986-12-16 1988-08-23 Schering Corporation Novel vaginal suppository
US5234940A (en) * 1989-07-28 1993-08-10 Queen's University Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
US5955490A (en) * 1989-07-28 1999-09-21 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US5079262A (en) * 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
US5422093A (en) * 1989-07-28 1995-06-06 Queen's University Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
JP3181062B2 (ja) * 1991-01-31 2001-07-03 帝國製薬株式会社 下部消化管崩壊経口製剤
JPH05213752A (ja) * 1992-02-06 1993-08-24 Fujisawa Asutora Kk 坐 剤
GB9504948D0 (en) * 1995-03-10 1995-04-26 Norwegian Radium Hospital Rese Compounds
US6992107B1 (en) * 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
CZ291132B6 (cs) * 1995-03-10 2002-12-11 Photocure Asa Estery kyselin 5-aminolevulových a farmaceutický prostředek s jejich obsahem
GB9700396D0 (en) * 1997-01-10 1997-02-26 Photocure As Photochemotherapeutic compositions
JP4162735B2 (ja) * 1997-02-26 2008-10-08 久光製薬株式会社 セロトニン受容体拮抗薬含有直腸投与製剤
JPH1112197A (ja) * 1997-06-18 1999-01-19 Cosmo Sogo Kenkyusho:Kk 悪性腫瘍診断剤及び治療剤
AU5486899A (en) * 1998-08-13 2000-03-06 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
JP3614305B2 (ja) * 1998-08-28 2005-01-26 株式会社オーバル 流量計の誤計数防止装置
DE10003620A1 (de) * 2000-01-28 2001-08-02 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln
DE10034673C1 (de) * 2000-07-17 2002-04-25 Medac Klinische Spezialpraep Dermales Applikationssystem für Aminolävulinsäure und seine Verwendung
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
WO2002013788A1 (en) * 2000-08-16 2002-02-21 The General Hospital Corporation D/B/A Massachusetts General Hospital Topical aminolevulinic acid-photodynamic therapy for acne vulgaris
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US7264629B2 (en) * 2001-11-09 2007-09-04 Qlt, Inc. Photodynamic therapy for the treatment of hair loss
US6723750B2 (en) * 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
US20040171601A1 (en) * 2002-07-31 2004-09-02 Dai Fukumura Photodynamic and sonodynamic therapy
GB0315671D0 (en) * 2003-07-04 2003-08-13 Chelsea And Westminster Nhs Tr Improvements in or relating to organic compounds
US20070225518A1 (en) * 2006-03-22 2007-09-27 Zvi Malik 5-Aminolevulinic acid salts and their use
GB0609809D0 (en) * 2006-05-17 2006-06-28 Photocure Asa Product
GB0724279D0 (en) * 2007-12-12 2008-01-23 Photocure Asa Use

Also Published As

Publication number Publication date
CA2708137C (en) 2016-11-22
WO2009074811A2 (en) 2009-06-18
KR20100095443A (ko) 2010-08-30
US20150031761A1 (en) 2015-01-29
RU2014112548A (ru) 2015-10-10
EP2684573A2 (en) 2014-01-15
NZ600028A (en) 2013-08-30
JP5863735B2 (ja) 2016-02-17
CA2708137A1 (en) 2009-06-18
RU2010123086A (ru) 2012-01-20
US20110020441A1 (en) 2011-01-27
EP2684573A3 (en) 2014-09-24
JP5686603B2 (ja) 2015-03-18
AU2008334426B2 (en) 2014-03-27
CN101896203A (zh) 2010-11-24
WO2009074811A3 (en) 2009-08-06
CN104306968A (zh) 2015-01-28
AU2008334426A1 (en) 2009-06-18
JP2014012725A (ja) 2014-01-23
EP2231188A2 (en) 2010-09-29
BRPI0821668A2 (pt) 2015-06-16
RU2521228C2 (ru) 2014-06-27
GB0724279D0 (en) 2008-01-23
JP2011507808A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
AU2008334426B2 (en) Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis
AU2010257752B2 (en) Solid compositions comprising 5-aminolevulinic acid
US20110293528A1 (en) Enema preparations and their use
US7022345B2 (en) Oral solid pharmaceutical formulations with pH-dependent multiphasic release
US8927761B2 (en) Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same
US20130178787A1 (en) Dry Compositions and Devices Containing Such Dry Compostions for Use in Photodynamic Therapy or Photodynamic Diagnosis
ES2852899T3 (es) Formulaciones estabilizadas de molindona
US20130211215A1 (en) Hyperosmotic preparations comprising 5-aminolevulinic acid or derivative as photosensitizing agent
AU2014200004B2 (en) Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis
GB2546128A (en) Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
GB2546356A (en) Solid products and their use

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 DEC 2015 BY COMPUTER PACKAGES INC.

Effective date: 20121227

LAPS Patent lapsed